骨修饰剂治疗肺癌骨转移的比较疗效:免疫治疗时代。

IF 2.6 4区 医学 Q2 ONCOLOGY
Future oncology Pub Date : 2025-08-01 Epub Date: 2025-07-01 DOI:10.1080/14796694.2025.2525744
Dongmei Sun, Hui Zhu, Qinhao Xu, Yujie Wang, Yuezheng Peng, Yaru Tian, Jinming Yu, Zhe Wang
{"title":"骨修饰剂治疗肺癌骨转移的比较疗效:免疫治疗时代。","authors":"Dongmei Sun, Hui Zhu, Qinhao Xu, Yujie Wang, Yuezheng Peng, Yaru Tian, Jinming Yu, Zhe Wang","doi":"10.1080/14796694.2025.2525744","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Denosumab and bisphosphonates are commonly used in clinical practice for lung cancer patients with bone metastasis to prevent skeletal-related events (SREs). The aim of this study was to evaluate the efficacy of these two bone-modifying agents(BMAs)in advanced lung cancer patients with bone metastasis in the era of immunotherapy.</p><p><strong>Methods: </strong>Electronic medical records of advanced lung cancer patients with bone metastasis between January 2020 and March 2023 were retrospectively reviewed. Overall survival (OS), progression-free survival (PFS), and the time to the first occurrence of SRE were calculated using the Kaplan - Meier method and were compared using the log-rank test.</p><p><strong>Results: </strong>Among the 227 included patients, denosumab significantly improved OS by 5.41 months compared with bisphosphonates (27.54 months <i>vs</i>. 22.13 months; hazard ratio (HR): 0.61; <i>p</i>  = 0.031). Denosumab also delayed the time to the first occurrence of SRE (undefined <i>vs</i>. 31.64 months; HR: 0.43, <i>p</i> = 0.005) and reduced the incidence of multiple SREs. However, the incidence of hypocalcemia at grade ≥ 3 was higher in the denosumab group than in the bisphosphonate group (8.6% <i>vs</i>. 3.0%).</p><p><strong>Conclusions: </strong>In patients with bone metastatic lung cancer, the efficacy of denosumab was significantly higher than that of bisphosphonate.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2483-2493"},"PeriodicalIF":2.6000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330236/pdf/","citationCount":"0","resultStr":"{\"title\":\"Comparative efficacy of bone-modifying agents in the treatment of lung cancer bone metastases: immunotherapy era.\",\"authors\":\"Dongmei Sun, Hui Zhu, Qinhao Xu, Yujie Wang, Yuezheng Peng, Yaru Tian, Jinming Yu, Zhe Wang\",\"doi\":\"10.1080/14796694.2025.2525744\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aim: </strong>Denosumab and bisphosphonates are commonly used in clinical practice for lung cancer patients with bone metastasis to prevent skeletal-related events (SREs). The aim of this study was to evaluate the efficacy of these two bone-modifying agents(BMAs)in advanced lung cancer patients with bone metastasis in the era of immunotherapy.</p><p><strong>Methods: </strong>Electronic medical records of advanced lung cancer patients with bone metastasis between January 2020 and March 2023 were retrospectively reviewed. Overall survival (OS), progression-free survival (PFS), and the time to the first occurrence of SRE were calculated using the Kaplan - Meier method and were compared using the log-rank test.</p><p><strong>Results: </strong>Among the 227 included patients, denosumab significantly improved OS by 5.41 months compared with bisphosphonates (27.54 months <i>vs</i>. 22.13 months; hazard ratio (HR): 0.61; <i>p</i>  = 0.031). Denosumab also delayed the time to the first occurrence of SRE (undefined <i>vs</i>. 31.64 months; HR: 0.43, <i>p</i> = 0.005) and reduced the incidence of multiple SREs. However, the incidence of hypocalcemia at grade ≥ 3 was higher in the denosumab group than in the bisphosphonate group (8.6% <i>vs</i>. 3.0%).</p><p><strong>Conclusions: </strong>In patients with bone metastatic lung cancer, the efficacy of denosumab was significantly higher than that of bisphosphonate.</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\" \",\"pages\":\"2483-2493\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12330236/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2525744\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2525744","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:Denosumab联合双膦酸盐用于肺癌骨转移患者预防骨相关事件(SREs)的临床应用。本研究的目的是评价这两种骨修饰剂(BMAs)在免疫治疗时代晚期肺癌骨转移患者中的疗效。方法:回顾性分析2020年1月至2023年3月晚期肺癌骨转移患者的电子病历。使用Kaplan - Meier方法计算总生存期(OS)、无进展生存期(PFS)和到SRE首次发生的时间,并使用log-rank检验进行比较。结果:在227例纳入的患者中,与双膦酸盐相比,denosumab显著改善OS 5.41个月(27.54个月vs 22.13个月;风险比(HR): 0.61;P = 0.031)。Denosumab也延迟了SRE首次发生的时间(未定义vs. 31.64个月;HR: 0.43, p = 0.005),降低了多发性SREs的发生率。然而,低钙血症≥3级的发生率在denosumab组高于双膦酸盐组(8.6%比3.0%)。结论:在骨转移性肺癌患者中,denosumab的疗效显著高于双膦酸盐。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Comparative efficacy of bone-modifying agents in the treatment of lung cancer bone metastases: immunotherapy era.

Aim: Denosumab and bisphosphonates are commonly used in clinical practice for lung cancer patients with bone metastasis to prevent skeletal-related events (SREs). The aim of this study was to evaluate the efficacy of these two bone-modifying agents(BMAs)in advanced lung cancer patients with bone metastasis in the era of immunotherapy.

Methods: Electronic medical records of advanced lung cancer patients with bone metastasis between January 2020 and March 2023 were retrospectively reviewed. Overall survival (OS), progression-free survival (PFS), and the time to the first occurrence of SRE were calculated using the Kaplan - Meier method and were compared using the log-rank test.

Results: Among the 227 included patients, denosumab significantly improved OS by 5.41 months compared with bisphosphonates (27.54 months vs. 22.13 months; hazard ratio (HR): 0.61; p  = 0.031). Denosumab also delayed the time to the first occurrence of SRE (undefined vs. 31.64 months; HR: 0.43, p = 0.005) and reduced the incidence of multiple SREs. However, the incidence of hypocalcemia at grade ≥ 3 was higher in the denosumab group than in the bisphosphonate group (8.6% vs. 3.0%).

Conclusions: In patients with bone metastatic lung cancer, the efficacy of denosumab was significantly higher than that of bisphosphonate.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Future oncology
Future oncology ONCOLOGY-
CiteScore
5.40
自引率
3.00%
发文量
335
审稿时长
4-8 weeks
期刊介绍: Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信